The European Medicines Agency recommends the approval of the new drug Daraxonrasib for the treatment of metastatic pancreatic cancer, which can double patients' survival time compared to conventional chemotherapy. #Bauchspeicheldrüsenkrebs #Krebsforschung #Gesundheit (translated)











